Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications
Feasibility, Acceptability, and Preliminary Effects of a Nurse-Delivered Self-Management Program for Individuals with Inflammatory Bowel Disease: A Pilot Randomized Controlled Trial.
Journal: Digestive diseases and sciences
Published: May 18, 2026
Correlation of Fecal, Plasma, Serum, and Salivary Calprotectin to Endoscopic and Histologic Outcomes in Patients With Crohn's Disease: A Pilot Study.
Journal: Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
Published: July 18, 2025
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease.
Journal: Inflammatory bowel diseases
Published: March 03, 2025
Epidemiology of Patients With Dance-Related Injuries Presenting to Medical Staff at Breaking Competitions in the United States, 2021-2023.
Journal: Journal of dance medicine & science : official publication of the International Association for Dance Medicine & Science
Published: February 07, 2025
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study.
Journal: The American journal of gastroenterology
Published: November 18, 2024
Upadacitinib Results in Endoscopic Remission in Patients With Inflammatory Bowel Disease and Prior Tofacitinib Failure.
Journal: Journal of clinical gastroenterology
Published: October 31, 2024
Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: October 08, 2024
Discordance between endoscopic and histopathologic assessment in ileal Crohn's disease.
Journal: World journal of gastrointestinal endoscopy
Published: September 09, 2024
Mycophenolate Mofetil Appears Effective for the Treatment of Patients With Refractory Crohn's Disease.
Journal: Crohn's & colitis 360
Published: August 01, 2024
Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis.
Journal: The American journal of gastroenterology
Published: July 30, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Journal: Inflammatory bowel diseases
Published: July 19, 2024
Certolizumab Pegol Treatment in Patients With Crohn's Disease: Final Safety Data From the SECURE Registry.
Journal: Crohn's & colitis 360
Published: June 04, 2024
Last Updated: 09/26/2026